Large Multi Center Study Suggests New Genetic Markers For Crohn's Disease
What is believed to be the largest study of its kind for the genetic roots of inflammatory bowel diseases has suggested new links to Crohn's Disease as well as further evidence that some people of Jewish descent are more likely to develop it.
Cimzia reg; Approved In United States For Crohn's Disease
According to a press release from UCB on April 22, 2008, a newpegylatedanti-TNF^I, will be made available in the United States under thename Cimzia in the next few days. This will be a new, promising option for patients suffering from moderate to severe Crohn'sDisease.
FDA Approval Of Cimzia R For Crohn's Disease Represents Latest Milestone For Nektar's PEGylation Technology Platform
The U.S. Food and Drug Administration (FDA) approved UCB's Cimzia(R) (certolizumab pegol) for reducing the signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderate to severe active disease who have an inadequate response to conventional therapy.
FDA Approves Cimzia To Treat Crohn's Disease
A new drug has been approved to help sufferers of Crohn's disease, the U.S. Food and Drug Administration announced today. Cimzia (certolizumab pegol) received approval for adults with moderate to severe Crohn's disease who have not responded to conventional therapies.
For Crohn's Patients, Omega-3 Fatty Acids Not Effective In Preventing Relapse
Administrationof omega-3 fatty acid supplements did not appear to improve the rate ofrelapse in patients with Crohn's disease, according to a study releasedon April 9, 2008 in JAMA. Crohn'sDisease is a gastrointestinal disorder which is indicated bychronicinflammation of the wall of the digestive tract, usually in the ileumor large intestines.
UCB To Appeal European Negative Opinion On CIMZIA R For The Treatment Of Patients With Crohn's Disease
UCB announced that it has been informed by the European Medicines Agency (EMEA) that the Committee for Medicinal Products for Human Use (CHMP) has adopted a negative opinion on the market authorisation application (MAA) in the EU for CIMZIA(R) certolizumab pegol) in the treatment of patients with Crohn's disease.
CHMP Adopts Negative Opinion On Appeal On European Application For Natalizumab For The Treatment Of Crohn's Disease
Elan Corporation, plc (NYSE: ELN) and Biogen Idec (NASDAQ: BIIB) announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), has adopted a negative opinion on the marketing authorization for natalizumab as a treatment for Crohn's disease.
Callisto Announces Presentation On Guanilib At 2007 Crohn's And Colitis Foundation National Research And Clinical Conference
Callisto Pharmaceuticals, Inc. (AMEX: KAL; FWB: CA4), a developer of new drug treatments in the fight against cancer and gastrointestinal diseases, announced that Dr. Kunwar Shailubhai, Sr. VP Discovery Research, will give an oral presentation covering preclinical data on Guanilib at the Crohn's and Colitis Foundation National Research and Clinical Conference - 6th Annual Advances in the Inflammatory Bowel Diseases during Dec.
Differing Physician And Patient Perceptions Regarding Impact Of UC Revealed by Nationwide Survey
Nearly three out of four patients with ulcerative colitis (UC) consider feeling unwell to be a normal part of life, while gastroenterologists estimate this to be true for only 37 percent of their UC patients, according to results from a nationwide series of surveys presented at the 2007 Crohn's & Colitis Foundation's 6th Annual Advances in the Inflammatory Bowel Diseases conference.
Bacteria In Cows' Milk May Cause Crohn's Disease
Crohn's is a condition that affects one in 800 people in the UK and causes chronic intestinal inflammation, leading to pain, bleeding and diarrhoea.The team found that a bacterium called Mycobacterium paratuberculosis releases a molecule that prevents a type of white blood cell from killing E.